001     154935
005     20220930130031.0
024 7 _ |a 10.2174/1573406410666140428151318
|2 doi
024 7 _ |a 1573-4064
|2 ISSN
024 7 _ |a 1875-6638
|2 ISSN
037 _ _ |a FZJ-2014-04146
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Olma, Sebastian
|0 Extern
|b 0
|e Corresponding author
245 _ _ |a Synthesis and first evaluation of [18F]fluorocyano- and [18F]fluoronitro-quinoxalinedione as putative AMPA receptor antagonists
260 _ _ |a Bussum [u.a.]
|c 2015
|b Bentham Sc. Publ.
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1437642657_19510
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Abstract:Derivatives of quinoxalinedione (QX) were chosen as chemical lead for the development of new radioligands of the AMPA receptor, since there are several examples of QX-derivatives with high affinity. The radiosyntheses of the new compounds 6-[18F]fluoro-7-nitro-QX ([18F]FNQX) and 7-[18F]fluoro-6-cyano-QX ([18F]FCQX) with radiochemical yields of 8 ± 2 and 3 ± 2 %, respectively, as well as the evaluation of their binding properties to the AMPA-receptor were performed. A comparison of the Ki-values of the new QX-derivatives FCQX and FNQX with mono-substituted cyanoand nitro-QX shows negligibly small differences of affinity (within the range of 1.4 to 5 µM), but exhibits a tenfold lower affinity than derivatives with two electron withdrawing groups like the 7-cyano-6-nitro-compound CNQX and the 6,7- dinitro compound DNQX. Thus, with respect to the low affinity and a high non-specific binding with in vitro and ex vivo autoradiographic studies, the new compounds do not lend themselves for in vivo imaging.- See more at: http://www.eurekaselect.com/121871/article#sthash.JGpS3IVS.dpuf
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|x 0
|f POF III
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|x 1
|f POF III
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Ermert, Johannes
|0 P:(DE-Juel1)131818
|b 1
700 1 _ |a Sihver, Wiebke
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Coenen, Heinrich Hubert
|0 P:(DE-Juel1)131816
|b 3
773 _ _ |a 10.2174/1573406410666140428151318
|g Vol. 11, no. 1, p. 13 - 20
|0 PERI:(DE-600)2220268-7
|n 1
|p 13 - 20
|t Medicinal chemistry
|v 11
|y 2015
|x 1573-4064
909 C O |o oai:juser.fz-juelich.de:154935
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 Extern
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131818
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131816
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|2 G:(DE-HGF)POF3-500
|v Neuroimaging
|x 0
914 1 _ |y 2015
915 _ _ |a Peer review unknown
|0 StatID:(DE-HGF)0040
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a UNRESTRICTED
980 _ _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21